Comparative study of fecal calprotectin levels in ulcerative colitis versus irritable bowel syndrome.

Geethika Sai Satyavasukiaparna Garaga, Kalvakota Maninithya, Nadampalli Deepica Rani, Aksah Dayan

Abstract read

In one paragraph

Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Geethika Sai Satyavasukiaparna GaragaDepartment of Gastroenterology and Hepatology, Yashoda Hospitals, Hyderabad, Telangana, India.

Kalvakota ManinithyaDepartment of Medical Gastroenterology, Yashoda hospital, Hyderabad, Telangana, India.

Nadampalli Deepica RaniDepartment of General Medicine, Yashoda hospitals, Hyderabad, Telangana, India.

Aksah DayanDepartment of Medical Gastroenterology, Yashoda hospital, Hyderabad, Telangana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fecal calprotectin has been evaluated on its ability to differentiate between ulcerative colitis (UC) and irritable bowel syndrome (IBS). Hence, sixty patients were stratified according to clinical and histological characteristic as UC (Group A) and IBS (Group B). The levels of calprotectin in UC patients (623.5 0 g) were significantly higher than in IBS patients (36.4 0 g), (p < 0.001). The high presence was observed in 93.3 percent of UC subjects and only 6.7 percent of IBS subjects. Thus, fecal calprotectin works well in distinguishing UC and IBS, and facilitates the non-invasive diagnosis of UC.

Indexed as

ELISAFecal calprotectininflammatory bowel diseaseirritable bowel syndromenon-invasive biomarkerulcerative colitis

Identifiers

PMID41170089

DOI10.6026/973206300211850

PMCPMC12569858

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.